Applicant, as named in the Orange Book

Journey

Next listed expiry: Zilxi on 1 Oct 2030. 4 products with live protection, 2 without.

Products with listed protection

Drug	Ingredient	Earliest generic entry	Basis
Zilxi NDA 213690 minocycline hydrochloride	minocycline hydrochloride	1 Oct 2030 patent	patent
Qbrexza NDA 210361 glycopyrronium tosylate	glycopyrronium tosylate	28 Feb 2033 patent	patent
Amzeeq NDA 212379 minocycline hydrochloride	minocycline hydrochloride	8 Sep 2037 patent, carve-out possible	patent, carve-out possible
Emrosi NDA 219015 minocycline hydrochloride	minocycline hydrochloride	7 Jan 2039 patent, carve-out possible	patent, carve-out possible

Recent events

Qbrexza · First generic approved · ANDA 214448, Padagis UsApproved 3 Apr 2026Detected 25 Oct 2026
Qbrexza · Generic approved · ANDA 214448, Padagis UsApproved 3 Apr 2026Detected 25 Oct 2026
Ximino · Enters 12-month window basis: patentListed date 2 Apr 2027Detected 24 Oct 2026
Ximino · Enters 12-month window basis: patentListed date 2 Apr 2027Detected 24 Oct 2026
Ximino · Enters 12-month window basis: patentListed date 2 Apr 2027Detected 24 Oct 2026

Products without listed protection (2)

Drug	Ingredient	Earliest generic entry	Basis
Eurax NDA 006927 crotamiton	crotamiton	open now no listed protection	no listed protection
Exelderm NDA 018737 sulconazole nitrate	sulconazole nitrate	open now no listed protection	no listed protection